ArticleJournal of the Egyptian National Cancer Institute2026
An insilico analysis: three upregulated microRNAs as potential diagnostic biomarkers of Papillary Thyroid Carcinoma (PTC).
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPapillary thyroid carcinoma (PTC) represents the most prevalent subtype of thyroid cancer. Accumulating evidence indicates that specific microRNAs are consistently dysregulated in PTC and may hold value as biomarker candidates. Accordingly, this study aims to prioritize consistently upregulated microRNAs associated with PTC using an integrative in silico analysis of publicly available datasets.
methodsThis study conducted a comprehensive analysis of miRNA expression patterns using datasets available through A Database of Differentially Expressed miRNAs in Human Cancers (dbDEMC). The dataset was then processed through a data mining approach with a cutoff of P-value < 0.05 and log2FC > 1.5 to identify miRNAs that were significantly and consistently upregulated in the datasets. The target genes are predicted through miRDIP, miRTarBase, miRPathDB, and GEPIA2. Gene ontology and pathway enrichment analysis were performed in ShinyGO and EnrichR. To assess the diagnostic ability of the three miRNAs, CancerMIRNome is used to identify the ROC curve analysis results of each miRNA.
resultsThis exploratory in silico analysis identified 85 differentially expressed miRNAs in PTC, with hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p consistently upregulated across datasets. Functional enrichment and TCGA-based ROC analyses suggest that these miRNAs may have biological and discriminatory relevance in PTC. However, these findings are hypothesis-generating and require further experimental and clinical validation before any diagnostic application can be considered.
conclusionIn summary, our study identified the potential of hsa-miR-221-3p, hsa-miR-222-3p, and hsa-miR-146b-5p as potential diagnostic biomarkers of PTC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.